Angiogenesis - still a worthwhile target for breast cancer therapy?
作者信息
Lord Simon, Harris Adrian L
机构信息
Molecular Oncology Laboratories, University Department of Medical Oncology, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, UK.
出版信息
Breast Cancer Res. 2010 Dec 20;12 Suppl 4(Suppl 4):S19. doi: 10.1186/bcr2748.
Abstract
摘要
相似文献
1
Angiogenesis - still a worthwhile target for breast cancer therapy?
Breast Cancer Res. 2010 Dec 20;12 Suppl 4(Suppl 4):S19. doi: 10.1186/bcr2748.
2
Hypoxia-inducible factor in cancer angiogenesis: structure, regulation and clinical perspectives.
Crit Rev Oncol Hematol. 2009 May;70(2):93-102. doi: 10.1016/j.critrevonc.2009.01.001. Epub 2009 Jan 31.
3
Breast tumour angiogenesis.
Breast Cancer Res. 2007;9(6):216. doi: 10.1186/bcr1796.
4
Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
Cancer J. 2008 May-Jun;14(3):170-7. doi: 10.1097/PPO.0b013e318178d9de.
5
Bevacizumab in the treatment of breast cancer.
Cancer Treat Rev. 2010 Feb;36(1):75-82. doi: 10.1016/j.ctrv.2009.10.007. Epub 2009 Nov 22.
6
Vascular endothelial growth factor and bevacitumab in breast cancer.
Breast Cancer. 2007;14(2):163-73. doi: 10.2325/jbcs.968.
7
Antiangiogenic agents in breast cancer.
Cancer Invest. 2007 Oct;25(7):518-26. doi: 10.1080/07357900701648516.
8
Angiogenesis as a therapeutic target in breast cancer.
Mini Rev Med Chem. 2012 Oct;12(12):1230-8. doi: 10.2174/138955712802761988.
9
Bevacizumab pharmacogenetics in tumor treatment: still looking for the right pieces of the puzzle.
Pharmacogenomics. 2011 Aug;12(8):1077-80. doi: 10.2217/pgs.11.75.
10
Mechanisms of disease: angiogenesis and the management of breast cancer.
Nat Clin Pract Oncol. 2007 Sep;4(9):536-50. doi: 10.1038/ncponc0905.
引用本文的文献
1
Targeting Angiogenesis in Breast Cancer: Current Evidence and Future Perspectives of Novel Anti-Angiogenic Approaches.
Front Pharmacol. 2022 Feb 25;13:838133. doi: 10.3389/fphar.2022.838133. eCollection 2022.
2
The Response of Macrophages and Neutrophils to Hypoxia in the Context of Cancer and Other Inflammatory Diseases.
Mediators Inflamm. 2016;2016:2053646. doi: 10.1155/2016/2053646. Epub 2016 Feb 29.
3
Ethanol extract of Gleditsia sinensis thorn suppresses angiogenesis in vitro and in vivo.
BMC Complement Altern Med. 2012 Dec 4;12:243. doi: 10.1186/1472-6882-12-243.
本文引用的文献
1
Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy.
Ann Oncol. 2010 Sep;21(9):1765-1771. doi: 10.1093/annonc/mdq052. Epub 2010 Mar 16.
2
Targeted contrast-enhanced ultrasound imaging of tumor angiogenesis with contrast microbubbles conjugated to integrin-binding knottin peptides.
J Nucl Med. 2010 Mar;51(3):433-40. doi: 10.2967/jnumed.109.068007. Epub 2010 Feb 11.
3
Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab.
Clin Cancer Res. 2009 Dec 15;15(24):7652-7657. doi: 10.1158/1078-0432.CCR-09-1493.
4
Hypoxia-inducible factor 2 regulates hepatic lipid metabolism.
Mol Cell Biol. 2009 Aug;29(16):4527-38. doi: 10.1128/MCB.00200-09. Epub 2009 Jun 15.
5
G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models.
Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6742-7. doi: 10.1073/pnas.0902280106. Epub 2009 Apr 3.
6
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.
Cancer Cell. 2009 Mar 3;15(3):220-31. doi: 10.1016/j.ccr.2009.01.027.
7
Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity.
Br J Cancer. 2008 Nov 18;99(10):1564-71. doi: 10.1038/sj.bjc.6604741. Epub 2008 Oct 21.
8
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.
J Clin Oncol. 2008 Oct 1;26(28):4672-8. doi: 10.1200/JCO.2008.16.1612.
9
Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.
J Clin Oncol. 2008 Oct 20;26(30):4899-905. doi: 10.1200/JCO.2008.17.4789. Epub 2008 Sep 15.
10
Pericyte coverage decreases invasion of tumour cells into blood vessels in prostate cancer xenografts.
Prostate Cancer Prostatic Dis. 2009;12(1):41-6. doi: 10.1038/pcan.2008.33. Epub 2008 Jun 3.
Zotero 插件